eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.

News

Inquiries

Pure Biologics establishes Doto Medical special purpose vehicle

2 December

2022

Pure Biologics establishes Doto Medical special purpose vehicle

Pure Biologics establishes the Doto Medical special purpose vehicle and signs an agreement with the renowned international business advisor Clairfield Partners to accelerate the commercialization of the PB103 aptamer project.

Pure Biologics webinar – year summary and project updates

25 November

2022

Pure Biologics webinar – year summary and project updates

Webinar with the management.

Two Pure Biologics projects qualified for funding in the Medical Research Agency grant call

22 November

2022

Two Pure Biologics projects qualified for funding in the Medical Research Agency grant call

Two projects have been qualified for funding under the Medical Research Agency (Agencja Badań Medycznych) grant call for the development of targeted or personalized medicine based on cell therapies or protein products.